David Aggen, MD
@davidaggen.bsky.social
Genitourinary Oncologist, NYC
Variant histologies in bladder cancer are like different genres of music
Same stage - different openers and headliners
Watch here ➡️ x.com/uromigos/sta...
Same stage - different openers and headliners
Watch here ➡️ x.com/uromigos/sta...
October 25, 2025 at 1:15 AM
Variant histologies in bladder cancer are like different genres of music
Same stage - different openers and headliners
Watch here ➡️ x.com/uromigos/sta...
Same stage - different openers and headliners
Watch here ➡️ x.com/uromigos/sta...
🎶 Wondering how to tackle variant histologies in bladder cancer?
🎧 Watch here ⬇️
x.com/uromigos/sta...
@Uromigos @Dr_Aggen @BladderCancerUS
#BladderCancer #UroOnc #GUonc #PathTwitter
🎧 Watch here ⬇️
x.com/uromigos/sta...
@Uromigos @Dr_Aggen @BladderCancerUS
#BladderCancer #UroOnc #GUonc #PathTwitter
Uromigos on X: "The UromigosLive 2025 meeting presents #UromigosShorts videos on GU Oncology topics. The videos with the most views win a prize at #UromigosLive November 7-8th in Nashville, TN. Below, Dr. David Aggen discusses : Variant Histology Bladder Cancer. https://t.co/h3DFbgnz3G" / X
The UromigosLive 2025 meeting presents #UromigosShorts videos on GU Oncology topics. The videos with the most views win a prize at #UromigosLive November 7-8th in Nashville, TN. Below, Dr. David Aggen discusses : Variant Histology Bladder Cancer. https://t.co/h3DFbgnz3G
x.com
October 24, 2025 at 9:18 PM
🎶 Wondering how to tackle variant histologies in bladder cancer?
🎧 Watch here ⬇️
x.com/uromigos/sta...
@Uromigos @Dr_Aggen @BladderCancerUS
#BladderCancer #UroOnc #GUonc #PathTwitter
🎧 Watch here ⬇️
x.com/uromigos/sta...
@Uromigos @Dr_Aggen @BladderCancerUS
#BladderCancer #UroOnc #GUonc #PathTwitter
If you are looking for updates in #GU, join us in NYC on 4/30 for @OncLive #Stateofthescience summit. Free for healthcare professionals to register here!
shorturl.at/uTCUA
shorturl.at/uTCUA
April 25, 2025 at 2:10 PM
If you are looking for updates in #GU, join us in NYC on 4/30 for @OncLive #Stateofthescience summit. Free for healthcare professionals to register here!
shorturl.at/uTCUA
shorturl.at/uTCUA
Reposted by David Aggen, MD
#MattMilowsky with updated #Checkmate274 trial - adjuvant nivolumab after cystectomy improves time to recurrence & overall survival in #bladdercancer. Sets up ongoing #Alliance #MODERN trial! @ascocancer.bsky.social #GU25
February 14, 2025 at 4:44 PM
#MattMilowsky with updated #Checkmate274 trial - adjuvant nivolumab after cystectomy improves time to recurrence & overall survival in #bladdercancer. Sets up ongoing #Alliance #MODERN trial! @ascocancer.bsky.social #GU25
Congrats to Vinod Balachandran, a surgeon-scientist and Director of The Olayan Center for Cancer Vaccines at MSK, for being named to the inaugural edition of the @washingtonpost's Next 50, a list of up-and-coming changemakers shaping society in 2025.
bit.ly/3CMJhN6
bit.ly/3CMJhN6
Memorial Sloan Kettering Cancer Center Surgeon-Scientist, Vinod Balachandran, MD, Named to The Washington Post Next 50
Memorial Sloan Kettering Cancer Center (MSK) is pleased to announce The Washington Post has named Vinod Balachandran, MD, surgeon-scientist and Director of The Olayan Center for Cancer Vaccines at MSK...
bit.ly
February 13, 2025 at 5:30 PM
Congrats to Vinod Balachandran, a surgeon-scientist and Director of The Olayan Center for Cancer Vaccines at MSK, for being named to the inaugural edition of the @washingtonpost's Next 50, a list of up-and-coming changemakers shaping society in 2025.
bit.ly/3CMJhN6
bit.ly/3CMJhN6
Reposted by David Aggen, MD
Our paper in @nature.com is finally published: a prospective trial of a personalized Neoantigen Vaccine in Kidney Cancer
www.nature.com/articles/s41...
This is teamwork with @danafarber.bsky.social @yalecancer.bsky.social @harvardmed.bsky.social + Wu lab
www.nature.com/articles/s41...
www.nature.com/articles/s41...
This is teamwork with @danafarber.bsky.social @yalecancer.bsky.social @harvardmed.bsky.social + Wu lab
www.nature.com/articles/s41...
February 5, 2025 at 7:18 PM
Our paper in @nature.com is finally published: a prospective trial of a personalized Neoantigen Vaccine in Kidney Cancer
www.nature.com/articles/s41...
This is teamwork with @danafarber.bsky.social @yalecancer.bsky.social @harvardmed.bsky.social + Wu lab
www.nature.com/articles/s41...
www.nature.com/articles/s41...
This is teamwork with @danafarber.bsky.social @yalecancer.bsky.social @harvardmed.bsky.social + Wu lab
www.nature.com/articles/s41...
Reposted by David Aggen, MD
An explainer about how health research funding happens and why this NIH funding cycle shutdown matters: www.msnbc.com/opinion/msnb...
Opinion | I’m a health researcher. NIH’s pause on research grants could have a devastating cost.
This is a potentially devastating event — not just for the scientific community, but for all Americans.
www.msnbc.com
January 24, 2025 at 11:39 PM
An explainer about how health research funding happens and why this NIH funding cycle shutdown matters: www.msnbc.com/opinion/msnb...
Gopa Iyer discussing the potential for platinum following EV + pembro for advanced UC #AUC3 #bladdercancer
January 24, 2025 at 8:24 PM
Gopa Iyer discussing the potential for platinum following EV + pembro for advanced UC #AUC3 #bladdercancer
Reposted by David Aggen, MD
This GU oncology family — wonderful first #AUC3 consensus conference!
@drchoueiri.bsky.social @pgrivasmdphd.bsky.social @davidaggen.bsky.social
@drchoueiri.bsky.social @pgrivasmdphd.bsky.social @davidaggen.bsky.social
January 24, 2025 at 4:08 AM
This GU oncology family — wonderful first #AUC3 consensus conference!
@drchoueiri.bsky.social @pgrivasmdphd.bsky.social @davidaggen.bsky.social
@drchoueiri.bsky.social @pgrivasmdphd.bsky.social @davidaggen.bsky.social
At #AUC3 this A.M. discussing what’s next for treatment of NMIBC and treatment of variant histology UC - Gopa Iyer and Josh Meeks chairing session this AM with talks from Andrea Necchi, Michiel Van der Heijden, and Roger Li #bladdercancer
January 24, 2025 at 2:35 PM
At #AUC3 this A.M. discussing what’s next for treatment of NMIBC and treatment of variant histology UC - Gopa Iyer and Josh Meeks chairing session this AM with talks from Andrea Necchi, Michiel Van der Heijden, and Roger Li #bladdercancer
Dr. Marie Carlo discussing the role of NGS and germline testing for RCC and non-clear cell RCC @MSKCancerCenter #auc3 #kidneycancer @BradMcG04 chairing session
January 23, 2025 at 9:04 PM
Dr. Marie Carlo discussing the role of NGS and germline testing for RCC and non-clear cell RCC @MSKCancerCenter #auc3 #kidneycancer @BradMcG04 chairing session
Dr. Motzer reviewing the treatment landscape for advanced kidney cancer. Discussing when is the right time to introduce belzutifan. @MSKCancerCenter #AUC3 #kidneycancer
January 23, 2025 at 6:34 PM
Dr. Motzer reviewing the treatment landscape for advanced kidney cancer. Discussing when is the right time to introduce belzutifan. @MSKCancerCenter #AUC3 #kidneycancer
Stellar overview of cytoreductive nephrectomy in the era of combination immunotherapy by Ari Hakimi #auc3 #kidneycancer
January 23, 2025 at 4:55 PM
Stellar overview of cytoreductive nephrectomy in the era of combination immunotherapy by Ari Hakimi #auc3 #kidneycancer
Reposted by David Aggen, MD
As we explore more and more HLA-specific immune based therapies, this from MSK in JAMA Onc shows that standard NGS testing can infer HLA genotypes. Other NGS providers have done/can do @adamjschoenfeld.bsky.social @mskcancercenter.bsky.social @davidaggen.bsky.social jamanetwork.com/journals/jam...
Next-Generation Sequencing for HLA Genotype Screening and Matching to HLA-Restricted Therapies
This case series evaluates whether human leukocyte antigen (HLA) genotype could be inferred from standard next-generation sequencing, comparing concordance with confirmatory whole-exome sequencing and...
jamanetwork.com
December 4, 2024 at 12:51 PM
As we explore more and more HLA-specific immune based therapies, this from MSK in JAMA Onc shows that standard NGS testing can infer HLA genotypes. Other NGS providers have done/can do @adamjschoenfeld.bsky.social @mskcancercenter.bsky.social @davidaggen.bsky.social jamanetwork.com/journals/jam...
Reposted by David Aggen, MD
Surgeon General Calls for Cancer Warnings on Alcohol www.nytimes.com/2025/01/03/h... I think American Cancer Society and @ascocancer.bsky.social @jrgralow.bsky.social should support this initiative @oncoalert.bsky.social
U.S. Surgeon General Calls for Cancer Warnings on Alcohol
Dr. Vivek Murthy’s report cites studies linking alcoholic beverages to at least seven malignancies, including breast cancer. But to add warning labels, Congress would have to act.
www.nytimes.com
January 4, 2025 at 2:45 AM
Surgeon General Calls for Cancer Warnings on Alcohol www.nytimes.com/2025/01/03/h... I think American Cancer Society and @ascocancer.bsky.social @jrgralow.bsky.social should support this initiative @oncoalert.bsky.social
Innovative therapies in GU cancers: Promising targets in #Urothelial and #Kidney cancer.- BL-B01D1: A bispecific ADC (EGFR/HER3) with a 40% response rate in advanced urothelial cancer.
- NKT2152: A HIF2a inhibitor for RCC, showing promise but with toxicity challenges > bit.ly/3OUcvfe
- NKT2152: A HIF2a inhibitor for RCC, showing promise but with toxicity challenges > bit.ly/3OUcvfe
Innovative Therapies in GU Cancers: Promising Targets in Urothelial and Kidney Cancer - Jonathan Rosenberg
Alicia Morgans speaks with Jonathan Rosenberg about two novel therapies presented at ESMO 2024. The discussion centers on BL-B01D1, a bispecific antibody-drug conjugate targeting EGFR and HER3 in adva...
bit.ly
December 13, 2024 at 10:24 AM
Innovative therapies in GU cancers: Promising targets in #Urothelial and #Kidney cancer.- BL-B01D1: A bispecific ADC (EGFR/HER3) with a 40% response rate in advanced urothelial cancer.
- NKT2152: A HIF2a inhibitor for RCC, showing promise but with toxicity challenges > bit.ly/3OUcvfe
- NKT2152: A HIF2a inhibitor for RCC, showing promise but with toxicity challenges > bit.ly/3OUcvfe
Reposted by David Aggen, MD
My heart sank when I heard the news that Felix Feng has passed away. Felix was such a gentle and uplifting force for so many of us who work in the same field - and for anyone he touched. Although he has left us, his impact will be felt forever. ow.ly/Uc3H50TSBiC
I just helped save a life
You can save one, too. Donate now.
ow.ly
December 11, 2024 at 10:55 AM
My heart sank when I heard the news that Felix Feng has passed away. Felix was such a gentle and uplifting force for so many of us who work in the same field - and for anyone he touched. Although he has left us, his impact will be felt forever. ow.ly/Uc3H50TSBiC
Reposted by David Aggen, MD
Rich Matulewicz #SUO24
“Blockbuster New Therapy for Cancer…. Smoking Cessation “.
@joshmeeks.bsky.social
@yawnyame.bsky.social
@wandering-gu.bsky.social
“Blockbuster New Therapy for Cancer…. Smoking Cessation “.
@joshmeeks.bsky.social
@yawnyame.bsky.social
@wandering-gu.bsky.social
December 4, 2024 at 9:23 PM
Rich Matulewicz #SUO24
“Blockbuster New Therapy for Cancer…. Smoking Cessation “.
@joshmeeks.bsky.social
@yawnyame.bsky.social
@wandering-gu.bsky.social
“Blockbuster New Therapy for Cancer…. Smoking Cessation “.
@joshmeeks.bsky.social
@yawnyame.bsky.social
@wandering-gu.bsky.social
#SUO24 Implementing Smoking Cessation in the Urologic Oncology Setting @RichMatulewicz
Urologists: the most trusted and utilized source of information regarding the cause and 🚬-related nature of the patient’s bladder ca diagnosis
@urotoday
Urologists: the most trusted and utilized source of information regarding the cause and 🚬-related nature of the patient’s bladder ca diagnosis
@urotoday
December 4, 2024 at 11:30 PM
#SUO24 Implementing Smoking Cessation in the Urologic Oncology Setting @RichMatulewicz
Urologists: the most trusted and utilized source of information regarding the cause and 🚬-related nature of the patient’s bladder ca diagnosis
@urotoday
Urologists: the most trusted and utilized source of information regarding the cause and 🚬-related nature of the patient’s bladder ca diagnosis
@urotoday
Reposted by David Aggen, MD
AI has a huge potential in #BladderCancer for diagnosis, prognostic and predictive assessment
Some questions remain to be answered related to:
▶️ Heterogeneity of disease
▶️ Interreader variability of pathology assessment
▶️ Which ground truth to apply? #AI #MachineLearning @oncoalert.bsky.social
Some questions remain to be answered related to:
▶️ Heterogeneity of disease
▶️ Interreader variability of pathology assessment
▶️ Which ground truth to apply? #AI #MachineLearning @oncoalert.bsky.social
Day One of #BLADDR24
Dr Eva Maria Compérat
Role of AI for diagnosis and monitoring #BladderCancer
Emphasizes the broad potential of AI in diagnosing and monitoring
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Dr Eva Maria Compérat
Role of AI for diagnosis and monitoring #BladderCancer
Emphasizes the broad potential of AI in diagnosing and monitoring
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
November 27, 2024 at 9:30 AM
AI has a huge potential in #BladderCancer for diagnosis, prognostic and predictive assessment
Some questions remain to be answered related to:
▶️ Heterogeneity of disease
▶️ Interreader variability of pathology assessment
▶️ Which ground truth to apply? #AI #MachineLearning @oncoalert.bsky.social
Some questions remain to be answered related to:
▶️ Heterogeneity of disease
▶️ Interreader variability of pathology assessment
▶️ Which ground truth to apply? #AI #MachineLearning @oncoalert.bsky.social
We are excited to enroll patients with LN + bladder cancer on our neoadjuvant enfortumab vedotin + pembrolizumab trial @mskcc.bsky.sm
Now enrolling patients with N1-N3 disease #BLCSM
6 Cycles EV + P -> Cystectomy -> Pembrolizumab
www.mskcc.org/cancer-care/...
Now enrolling patients with N1-N3 disease #BLCSM
6 Cycles EV + P -> Cystectomy -> Pembrolizumab
www.mskcc.org/cancer-care/...
A Phase II Study of Enfortumab Vedotin and Pembrolizumab Immunotherapy Given Before Surgery in People with Bladder Cancer
Full Title Enfortumab Vedotin in Combination with Pembrolizumab for Locally Advanced and/or Node Positive Urothelial Carcinoma Prior to Surgery (EV-ECLIPSE) Purpose Researchers in this study are asses...
www.mskcc.org
November 26, 2024 at 10:41 PM
We are excited to enroll patients with LN + bladder cancer on our neoadjuvant enfortumab vedotin + pembrolizumab trial @mskcc.bsky.sm
Now enrolling patients with N1-N3 disease #BLCSM
6 Cycles EV + P -> Cystectomy -> Pembrolizumab
www.mskcc.org/cancer-care/...
Now enrolling patients with N1-N3 disease #BLCSM
6 Cycles EV + P -> Cystectomy -> Pembrolizumab
www.mskcc.org/cancer-care/...